- Home
- MGTX vs ZVRA Comparison
MGTX vs ZVRA Comparison
Compare MGTX & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- ZVRA
- Stock Information
- Founded
- MGTX 2015
- ZVRA 2006
- Country
- MGTX United States
- ZVRA United States
- Employees
- MGTX N/A
- ZVRA N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- ZVRA Health Care
- Exchange
- MGTX Nasdaq
- ZVRA Nasdaq
- Market Cap
- MGTX 670.2M
- ZVRA 627.7M
- IPO Year
- MGTX N/A
- ZVRA 2015
- Fundamental
- Price
- MGTX $7.83
- ZVRA $9.44
- Analyst Decision
- MGTX Strong Buy
- ZVRA Strong Buy
- Analyst Count
- MGTX 2
- ZVRA 10
- Target Price
- MGTX $24.00
- ZVRA $22.67
- AVG Volume (30 Days)
- MGTX 522.1K
- ZVRA 1.6M
- Earning Date
- MGTX 08-14-2025
- ZVRA 08-12-2025
- Dividend Yield
- MGTX N/A
- ZVRA N/A
- EPS Growth
- MGTX N/A
- ZVRA N/A
- EPS
- MGTX N/A
- ZVRA N/A
- Revenue
- MGTX $37,917,000.00
- ZVRA $62,020,000.00
- Revenue This Year
- MGTX $145.67
- ZVRA $303.00
- Revenue Next Year
- MGTX $167.61
- ZVRA $77.66
- P/E Ratio
- MGTX N/A
- ZVRA N/A
- Revenue Growth
- MGTX 366.84
- ZVRA 161.81
- 52 Week Low
- MGTX $3.85
- ZVRA $6.19
- 52 Week High
- MGTX $8.98
- ZVRA $13.16
- Technical
- Relative Strength Index (RSI)
- MGTX 49.11
- ZVRA 39.30
- Support Level
- MGTX $7.43
- ZVRA $8.91
- Resistance Level
- MGTX $8.63
- ZVRA $10.15
- Average True Range (ATR)
- MGTX 0.45
- ZVRA 0.65
- MACD
- MGTX -0.06
- ZVRA -0.22
- Stochastic Oscillator
- MGTX 40.89
- ZVRA 22.80
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.